Based on this, attempts have been made to treat ABPA with biologics, including omalizumab (anti-IgE), mepolizumab (anti-IL-5), benralizumab (anti-IL-5R), dupilumab (anti-IL-4Rα), and tezepelumab (anti-TSLP) (144). The gene discussed is IL5; the disease is allergic bronchopulmonary aspergillosis.